The content on this site is intended for healthcare professionals only
Dr Timothy Yap recently discussed the PETRA trial with ecancer. This is a phase 1/2a clinical trial for saruparib, which is a next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) for patients with advanced solid tumours.
The study focused on individuals with BRCA1/2, PALB2, or RAD51C/D mutations.
The results of the trial showed that saruparib, the selective PARP1 inhibitor being investigated, demonstrated promising activity for patients with certain homologous recombination repair (HRR)-deficient breast cancers while also limiting toxicity.
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
EAU 2024: Bladder cancer latest
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
